People who receive AstraZeneca’s COVID-19 vaccine have a slightly increased risk of bleeding problems, according to a study published June 9 in Nature Medicine. Researchers observed adults in Scotland ...

Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of ...

The FDA has concluded that Andexxa's risk profile is no longer favorable. AstraZeneca will stop sales of Andexxa in US.

AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a ...

Since the drug’s approval, the US Food and Drug Administration (FDA) says it has received post-marketing safety data on ...

AstraZeneca (NASDAQ:AZN) said its medicine Ultomiris reduced the risk of relapse by 98.6%, compared to placebo, in certain patients with a type of central nervous system (CNS) disorder in a phase 3 ...

Europe's medicines regulator has said there's "no indication" that the Oxford-AstraZeneca Covid-19 vaccine has caused blood clots, as the list of countries temporarily halting the vaccine's rollout ...

(Reuters) - The U.S. Food and Drug Administration said it will review possible heart risks associated with AstraZeneca Plc's widely-used diabetes drug saxagliptin, marketed as Onglyza and Kombiglyze ...

LONDON (Reuters) - Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited ...

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

The purple profit machine driven by AstraZeneca's $6 billion flagship medication, Prilosec, finally wound down last year. Once the world's largest selling prescription drug, the patents have expired, ...